Physician profile
Mark D Shields
NPI 1366411555
$1,274.34
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $208 · 2021: $169 · 2022: $253 · 2023: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $311.35 | 2019-2023 | Xarelto |
| Olympus America INC. | $129.42 | 2023 | Itind System |
| Boston Scientific Corporation | $89.91 | 2020-2022 | |
| Sanofi Pasteur INC. | $71.34 | 2019-2020 | |
| Astellas Pharma US INC | $54.07 | 2019-2021 | |
| Radius Health, INC. | $53.50 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $48.92 | 2020-2022 | |
| Pfizer INC. | $46.68 | 2019-2022 | |
| Glaxosmithkline, LLC. | $46.64 | 2019 | |
| Novo Nordisk INC | $45.81 | 2021-2022 | |
| Amgen INC. | $34.72 | 2019-2020 | |
| Amarin Pharma, INC. | $33.35 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.76 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.37 | 2023 | Crysvita |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $23.77 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $22.42 | 2019 | |
| Shield Therapeutics INC | $21.39 | 2023 | Accrufer |
| Abbvie INC. | $21.00 | 2021 | |
| Gilead Sciences, INC. | $20.50 | 2021 | |
| Esperion Therapeutics, INC. | $18.90 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.37 | 2022 | |
| Edwards Lifesciences Corporation | $16.81 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Seqirus USA INC | $15.42 | 2020 | |
| Medtronic, INC. | $14.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.29 | 2023 | |
| Allergan, INC. | $11.09 | 2020 | |
| Bardy Diagnostics, INC. | $9.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.